Paper-Analytical Device for Saliva Biomarker Diagnostics

项目总结： 在美国，心力衰竭(HF)每年影响570万人，每9人中就有1人死于这种疾病。 在护理时测量诊断和预后生物标记物是减少心力衰竭相关死亡的关键，但 基于血液的侵入性诊断测试需要大量资源，而且成本高昂。对敏感的迫切需求 使用非侵入性样本的分析仍然是护理点诊断的迫切需要。在这里，我们建议 开发一种创新的解决方案，用于快速、灵敏和廉价地测量唾液中的生物标记物 都与心力衰竭相关。为了满足这一需求，一种纸基分析设备(PAD)结合了唾液样本 用灵敏的电化学生物传感器检测Galectin-3(Gal-3)和s100A7作为生物标志物 唾液中的HF将被开发出来。该项目由两个目标组成，1)展示一种敏感的、选择性的 S100A7和GAL-3电化学垫及2)快速高效加工垫的研制 唾液的粘度在几分钟内变化。该项目是亨利集团在 科罗拉多州立大学(CSU)和昆士兰科技大学(QUT)的Punyadeera小组 在澳大利亚。国际合作是合理的，因为亨利集团拥有港口及机场发展区的专业知识和 Punyadeera集团拥有基于唾液的诊断经验。一旦成功，我们将扩大这两个数字 以及心血管疾病和头颈部癌症的生物标记物的类型。我们还将做好扩张的准备 正在进行的唾液生物标记物的临床研究，以进一步验证它们作为非侵入性生物标记物的用途。

Project Summary: Heart failure (HF) affects 5.7M people annually in the United States with 1 in 9 deaths linked to the disorder. Measuring diagnostic and prognostic biomarkers at the point of care is key for reducing HF-related deaths but invasive blood-based diagnostic tests require extensive resources and are expensive. A critical need for sensitive assays that utilize non-invasive samples remains a pressing need for point-of-care diagnostics. Here, we propose to develop an innovative solution to rapid, sensitive, and inexpensive measurements of biomarkers in saliva that are correlated with HF. To address this need, a paper-based analytic device (PAD) that combines saliva sample processing with sensitive electrochemical biosensors to detect galectin-3 (Gal-3) and s100A7 as biomarkers of HF in saliva will be developed. The project consists of two aims, 1) demonstration of a sensitive, selective electrochemical PAD for s100A7 and Gal-3 and 2) development of a PAD that can rapidly and efficiently process saliva of varying viscosities in minutes. This project is an international collaboration between the Henry group at Colorado State University (CSU) and the Punyadeera group at the Queensland University of Technology (QUT) in Australia. The international collaboration is justified because the Henry group has expertise in PADs and the Punyadeera group has experience with saliva-based diagnostics. Once successful, we will expand both the number and type of biomarkers for both cardiovascular disease and head/neck cancers. We will also be poised to expand on-going clinical studies of saliva-based biomarkers to further validate their use as non-invasive biomarkers.